Oncology
Analyst Available to Comment on Impact to the Pharmaceutical Industry of U.S. Senate Committee Approval of Biogenerics Legislation
Published in Medical Letter on the CDC and FDA, July 15th, 2007
Andrew Merseth, analyst at Decision Resources is available to comment on the impact to the pharmaceutical industry of the U.S. Senate committee's approval of biogenerics legislation. A U.S. Senate committee voted on Wednesday in favor of legislation that would allow the FDA to approve biogeneric drugs, and the bill, "The Biologics Price Competition and Innovation Act of 2007," will now head for the Senate floor. Biotechnology firms who oppose the bill have suggested that their products are too difficult to copy without risking dangerous side effects.
Decision Resources recently conducted a survey at the annual meeting of the American Society of Clinical Oncology (ASCO)...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Anemia
Community Oncology explores pitched debate over anemia-fighting drugs - Epidemiology
Adding folic acid to bread could help in the fight against depression - Malaria
FDA Clears for Marketing First Quick Test for Malaria - Regulatory Actions
University Hospitals receives full accreditation from human research protection programs - Amyotrophic Lateral Sclerosis
CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS - Antibiotics
Wockhardt to launch Cefprozil, in the US, Eight FDA approval in 4 months - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
